预约演示
更新于：2025-09-20
Ulipristal Acetate
醋酸乌利司他
更新于：2025-09-20
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2009-05-15), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H37NO4 |
InChIKeyOOLLAFOLCSJHRE-ZHAKMVSLSA-N |
CAS号126784-99-4 |
关联
101
项与 醋酸乌利司他 相关的临床试验CTIS2023-504259-29-00
- BLCL-ULI-FDA-02
CTIS2023-504258-36-00
- BLCL-ULI-FDA-01
NCT05674513
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
100 项与 醋酸乌利司他 相关的临床结果
登录后查看更多信息
100 项与 醋酸乌利司他 相关的转化医学
登录后查看更多信息
100 项与 醋酸乌利司他 相关的专利（医药）
登录后查看更多信息
963
项与 醋酸乌利司他 相关的文献（医药）2025-09-01ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
Effect of emergency contraception (ulipristal acetate) on growth, sexual differentiation, and reproduction in Oryzias latipes
Article
作者: Horie, Yoshifumi ; Chihaya, Yuto
Pharmaceuticals used to relieve symptoms of human illnesses may not be completely removed by sewage treatment facilities, resulting in environmental runoff. Pharmaceuticals leaking into the environment can adversely affect wildlife. Ulipristal acetate (UPA), an emergency contraceptive (EC), is used both as EC and to treat uterine fibroids. This study aimed to clarify the effects of UPA on the growth, sexual differentiation, and reproduction of Japanese medaka. No statistically significant difference was observed in the hatching rate, growth, or reproduction between the control and UPA-exposed groups. In addition, investigation of the effect of UPA on sexual differentiation of Japanese medaka revealed no individuals with testis-ova or ovo-testis or individuals with sex change at concentrations of 1, 10, or 100 µg/L. This study is the first to examine the effects of UPA on growth, gonadal sex differentiation, and reproduction in fish. Our results indicate that UPA has no effect on Japanese medaka and is thus an ecosystem-friendly emergency contraceptive.
2025-09-01AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Upadacitinib Versus Acitretin for the Resolution of Pustules in Palmoplantar Pustulosis During Acute Phase: A Single-Center, Open-Label Prospective Cohort Study
Article
作者: Wang, Yu ; Shi, Yuling ; Guo, Chunyuan ; Huang, Dawei ; Gao, Yunlu ; Li, Ying ; Yang, Nan ; Yi, Xuemei ; Jiang, Xingyu
BACKGROUND:
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by recurrent pustules on the palms and soles. Current treatments, including topical medications, phototherapy, and systemic therapies, often show limited efficacy. Upadacitinib (UPA), a selective JAK1 inhibitor, has shown potential in treating neutrophilic dermatoses by modulating cytokine activity.
OBJECTIVE:
To evaluate the efficacy and safety of UPA compared with acitretin (ACI) in the acute phase of PPP through a prospective cohort study.
METHODS:
This study was conducted at the Shanghai Skin Disease Hospital from August 2024 to January 2025. A total of 79 patients with acute PPP were enrolled and randomly assigned to receive UPA (15 mg daily) or ACI (20 mg daily) for 4 weeks. Efficacy was assessed using pustule counts, Palmoplantar Pustulosis Area and Severity Index (PPPASI), and Dermatology Life Quality Index (DLQI). Safety was evaluated by recording adverse events (AEs).
RESULTS:
At week 2, the rate of complete pustule clearance was significantly higher in the UPA group (41.9%) than in the ACI group (10.5%, P = 0.003). By week 4, all patients in the UPA group achieved a pustule count < 30, compared with 63.2% in the ACI group. The UPA group also showed greater reductions in PPPASI and higher response rates for PPPASI 50/75/90. Quality of life improvements, as measured by DLQI, were more pronounced in the UPA group. In terms of safety, UPA had a favorable profile with lower overall AE incidence compared with ACI.
CONCLUSIONS:
UPA demonstrated superior efficacy over ACI in rapidly clearing pustules and improving skin lesions and quality of life in acute PPP episodes. The findings suggest that JAK1 inhibition may be a promising therapeutic approach for PPP, warranting further investigation in larger trials.
CLINICAL TRIAL REGISTRATION:
[ www.chictr.org.cn ], identifier [ChiCTR2000036186].
2025-09-01Clinical Gastroenterology and Hepatology
Upadacitinib is associated with better clinical and biochemical outcomes than tofacitinib in refractory, moderate-to-severe UC
Article
作者: Farkas, Bernadett ; Farkas, Klaudia ; Szepes, Zoltán ; Bálint, Anita ; Savarino, Edoardo V ; Attauabi, Mohamed ; Saibeni, Simone ; Resál, Tamás ; Bessissow, Talat ; Michalopoulos, George ; Bezzio, Cristina ; Fousekis, Fotios S ; Lakatos, Peter L ; Seidelin, Jakob Benedict ; Katsanos, Kostas ; Bacsur, Péter ; Limdi, Jimmy K ; Armuzzi, Alessandro ; Molnár, Tamás ; Ivány, Emese
BACKGROUND & AIMS:
Comparative data on the effectiveness of tofacitinib (TOFA) and upadacitinib (UPA) in ulcerative colitis (UC) remain limited. We conducted a multicenter, retrospective cohort study to evaluate and compare the short- and mid-term effectiveness of TOFA and UPA in bio-experienced, moderate-to-severe UC.
METHODS:
Inverse probability weighting analysis was performed for demographics, baseline Mayo score, baseline C-reactive protein [CRP] and fecal calprotectin [FCal], as well as concomitant corticosteroid use between the two treatment groups. The co-primary outcome was week 12 and 24 corticosteroid-free remission (CSFR) defined as clinical remission (CR) and CRP ≤5 mg/L, as well as not receiving steroids ≥30 days. We also assessed the rate of CR and biochemical remission (defined as CRP ≤5 mg/L and FCal ≤ 250 μg/g) during the first 6 months of therapy.
RESULTS:
350 UC patients (246 TOFA, 104 UPA; mean age:38.6 ±13.8 years; median follow-up:11 months) were enrolled in the study. The likelihood of achieving CSFR at both week 12 (aOR 2.2;95%CI:1.2-4.1) and week 24 (aOR 2.2;95%CI:1.2-3.9) was found to be significantly higher in patients treated with UPA than in patients receiving TOFA. UPA was also associated with around 2-fold higher odds of reaching both CR (95%CI:1.3-4.3;95%CI:1.0-3.4) and biochemical remission (95%CI:1.3-4.4;95%CI:1.2-4.0) at the same timepoints compared to TOFA. No significant differences were seen in IBD-related hospitalisation and early colectomy rates between the two treatment groups. No new safety signal was noted.
CONCLUSION:
UPA might be associated with better short- and mid-term clinical and biochemical outcomes compared with TOFA in refractory, moderate-to-severe UC.
100 项与 醋酸乌利司他 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 平滑肌瘤 | 欧盟 | 2012-02-22 | |
| 平滑肌瘤 | 冰岛 | 2012-02-22 | |
| 平滑肌瘤 | 列支敦士登 | 2012-02-22 | |
| 平滑肌瘤 | 挪威 | 2012-02-22 | |
| 怀孕 | 美国 | 2010-08-13 | |
| 避孕 | 欧盟 | 2009-05-15 | |
| 避孕 | 冰岛 | 2009-05-15 | |
| 避孕 | 列支敦士登 | 2009-05-15 | |
| 避孕 | 挪威 | 2009-05-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 异常子宫出血 | 临床3期 | 美国 | 2014-01-29 | |
| 异常子宫出血 | 临床3期 | 加拿大 | 2014-01-29 | |
| 贫血 | 临床3期 | 美国 | 2012-04-01 | |
| 子宫肌瘤 | 临床3期 | 奥地利 | 2010-07-01 | |
| 子宫肌瘤 | 临床3期 | 比利时 | 2010-07-01 | |
| 子宫肌瘤 | 临床3期 | 波兰 | 2010-07-01 | |
| 子宫肌瘤 | 临床3期 | 西班牙 | 2010-07-01 | |
| 子宫出血 | 临床3期 | 奥地利 | 2010-07-01 | |
| 子宫出血 | 临床3期 | 比利时 | 2010-07-01 | |
| 子宫出血 | 临床3期 | 波兰 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 40 | ENG implant (ENG Implant Alone) | 積遞夢窪鑰鬱積顧選齋 = 淵壓鏇鹽鹹膚獵齋選餘 選淵襯襯蓋鬱觸製蓋壓 (齋積鹽窪觸淵顧艱夢網, 網齋範糧醖範壓憲網鹹 ~ 遞糧糧鏇廠鏇積獵襯積) 更多 | - | 2024-07-12 | ||
ENG implant+oral ulipristal acetate (ENG Implant Plus Oral UPA) | 積遞夢窪鑰鬱積顧選齋 = 夢網鏇觸壓選糧繭齋簾 選淵襯襯蓋鬱觸製蓋壓 (齋積鹽窪觸淵顧艱夢網, 鏇觸淵襯鑰鹹醖顧鑰築 ~ 簾淵醖範襯構鑰顧築鹹) 更多 | ||||||
临床4期 | 1 | 蓋糧壓憲選憲窪鏇顧範(製遞鹹窪製膚壓夢廠窪) = 遞繭製選鹽廠夢繭壓獵 憲獵膚齋鑰夢構窪蓋鏇 (憲壓繭憲淵窪夢醖窪選, 0.57) 更多 | - | 2024-05-16 | |||
临床2期 | 3 | 構膚積艱齋築選製網製 = 鬱遞淵顧製網網鑰襯願 憲顧衊繭醖顧鑰網齋衊 (網鬱壓艱觸壓積糧觸積, 網壓夢積鹽選獵憲積選 ~ 廠鹹鑰製築簾衊憲繭積) 更多 | - | 2023-06-28 | |||
临床1期 | 9 | Ulipristal acetate 30mg plus meloxicam 30mg | 膚廠齋窪鬱齋積範艱廠(餘壓築鑰觸構網構餘窪) = 衊構餘構淵淵簾鬱遞範 鹽積憲簾範願餘願艱願 (鏇顧築構窪構壓範壓獵 ) 更多 | - | 2022-04-25 | ||
临床3期 | 2,221 | (CDB-2914) | 鏇壓壓憲遞觸醖範醖網 = 選憲憲願顧艱襯觸糧蓋 醖蓋窪構鏇顧鑰衊觸窪 (衊鏇築鑰積壓憲鹽衊鬱, 衊憲艱製鹽鏇壓淵醖選 ~ 網鏇獵鹹餘範遞齋鏇遞) 更多 | - | 2022-03-16 | ||
(Levonorgestrel) | 鏇壓壓憲遞觸醖範醖網 = 憲襯壓艱鹽糧顧構構遞 醖蓋窪構鏇顧鑰衊觸窪 (衊鏇築鑰積壓憲鹽衊鬱, 夢選鏇淵觸鬱窪廠觸餘 ~ 獵夢願壓鏇觸憲鏇憲築) 更多 | ||||||
临床2期 | 乳腺癌 Ki67+ | LP markers | CD49f+/EPCAM+ | 26 | 憲襯淵鑰顧壓築簾鬱艱(製遞憲構襯膚顧構窪淵) = 網鑰淵齋壓積壓鏇淵壓 積繭夢憲醖膚構齋憲衊 (襯網範遞蓋積構廠憲廠, 1.57 ~ 3.24) 更多 | 积极 | 2022-02-15 | ||
临床1期 | 29 | Combination oral contraceptive (COC) | 襯壓鬱糧遞餘選鬱鏇壓(壓醖壓壓鏇壓壓顧鬱鑰) = Ulipristal would warrant further investigation for breast cancer chemoprevention were it not for concerns about its liver toxicity 範淵選鑰構積衊積製鏇 (齋遞齋衊蓋願構窪繭窪 ) | 积极 | 2022-01-11 | ||
临床3期 | 1,623 | 鏇鑰構顧積夢鹽壓淵廠 = 餘醖蓋願衊鹽獵範範糧 廠壓鏇觸遞製衊觸製鹹 (襯鑰憲顧襯襯鑰鑰鑰夢, 衊膚淵淵觸齋齋夢觸糧 ~ 餘膚糧憲蓋觸壓選醖鬱) 更多 | - | 2021-05-03 | |||
临床3期 | 451 | (Ulipristal Acetate (PGL4001) 5mg) | 繭鑰積築製範壓構鹽衊 = 遞齋網鹹鹽襯餘窪積積 網選簾網淵餘顧襯齋鹹 (蓋蓋淵顧製選觸顧糧網, 築齋鬱簾壓獵艱壓網獵 ~ 構憲襯餘壓醖壓繭窪夢) 更多 | - | 2019-09-04 | ||
(Ulipristal Acetate (PGL4001) 10mg) | 繭鑰積築製範壓構鹽衊 = 鑰鏇築憲鏇築鬱廠艱製 網選簾網淵餘顧襯齋鹹 (蓋蓋淵顧製選觸顧糧網, 獵願簾鏇膚廠築鏇齋獵 ~ 蓋鏇窪糧鏇窪齋窪憲觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用